Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation.



Bone marrow transplantation, 2007; 40 (10) doi:10.1038/sj.bmt.1705840

Authors: Campregher P V, Gooley T, Scott B L, Moravec C, Sandmaier B et al.(4)

Affiliation: Fred Hutchinson Cancer Research Center, United States

Sample size: 14

Abstract: Allogeneic hematopoietic cell transplantation (HCT) represents a potentially curative approach for patients with myelodysplastic syndromes (MDSs). While a large proportion of HCT recipients become long-term disease-free survivors, recurrence of MDS remains the leading cause of mortality after HCT. The role of donor lymphocyte infusion (DLI) in patients with relapsed MDS after HCT is unclear. We report results among 16 patients treated with DLI for relapsed MDS after HCT at a single institution between March 1993 and February 2004. The cohort contained 10 men and 6 women with a median age of 49 (range, 22-67) years. CR with resolution of cytopenias and prior disease markers occurred in 3 of 14 patients who could be evaluated. Two patients survived without MDS for 68 and 65 months after DLI, respectively, but died with pneumonia. Grades II-IV acute GVHD and chronic GVHD occurred after DLI in 6 (43%) and 5 (36%) patients, respectively. All three responders developed grades III-IV acute GVHD and extensive chronic GVHD after DLI. Our results confirm prior reports that DLI can result in CR in some patients with recurrent MDS after transplant, but long-term survival is infrequent.














Related patents

Loading...

Map of newest papers for: relapsed after

The top research papers for the subject are placed on the map. Studies form clusters based on semantic relation.

Size of the point represents relevance of the paper.

You can pan and zoom the graph using mouse and mouse wheel.

Right click on the paper to:

  • a) open the paper
  • b) to open first author’s resume page.

Left click on keyword to add it to search.

Sign up to create your own map!